Texas-based Lexicon Pharmaceuticals Inc. has announced the successful completion of open-label, pioneer portions of the LX4211 trial and is now progressing to a Phase 2, placebo-controlled portion in type 1 diabetic study participants. The dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) is an investigational oral hypoglycemic drug that target type 1 diabetics.
http://bionews-tx.com/news/2013/05/14/lexicon-pharmaceuticals-advances-lx4211-in-type-1-diabetes-phase-2-trial/
Showing posts with label Lexicon. Show all posts
Showing posts with label Lexicon. Show all posts
Tuesday, May 14, 2013
Monday, February 25, 2013
Texas Biotech Company to Present in New York City on Wednesday
This Wednesday, February 27, 2013, New York City will host the RBC Markets Capital Healthcare Conference. One of Texas’ own biotech companies will be a presenter, providing an overview of their clinical developments and milestones. Brian Zambrowicz, Ph.D. is the Executive Vice President and Chief Scientific Officer of the Texas-based company Lexicon Pharmaceuticals Inc., and will at the present at the upcoming conference.
http://www.swbiosearch.com/2013/02/25/texas-biotech-company-to-present-in-new-york-city-on-wednesday/
Subscribe to:
Posts (Atom)